Gattex

Chemical Nameteduglutide
Dosage FormInjection (subcutaneous; 5 mg)
Drug ClassAnalogs
SystemDigestive
CompanyTakeda
Approval Year2012

Indication

  • For the treatment of patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support in adults and pediatric patients 1 year of age and older
Last updated on 4/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gattex (teduglutide) Prescribing Information.2012Shire-NPS Pharmaceuticals, Inc., Lexington, MA